PT  - JOURNAL ARTICLE
AU  - van der Meer, Dennis
AU  - Shadrin, Alexey A.
AU  - Stinson, Sara E.
AU  - Koch, Elise
AU  - Rokicki, Jaroslav
AU  - Rahman, Zillur
AU  - Bergstedt, Jacob
AU  - Ottas, Aigar
AU  - Sønderby, Ida E.
AU  - Rødevand, Linn
AU  - Fuhrer, Julian
AU  - Quintana, Daniel S.
AU  - Dale, Anders M.
AU  - O’Connell, Kevin S.
AU  - Djurovic, Srdjan
AU  - Lehto, Kelli
AU  - Alver, Maris
AU  - Milani, Lili
AU  - Andreassen, Ole A.
TI  - Divergent patterns of genetic overlap between severe mental disorders and metabolic markers
AID  - 10.1101/2024.11.04.24316693
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.04.24316693
4099  - http://medrxiv.org/content/early/2024/11/04/2024.11.04.24316693.short
4100  - http://medrxiv.org/content/early/2024/11/04/2024.11.04.24316693.full
AB  - Background Bipolar disorder (BIP), major depressive disorder (MDD) and schizophrenia (SCZ) are severe mental disorders (SMDs), each associated with poor cardiometabolic health. Mapping the genetic relationships of these highly heritable disorders with blood markers of metabolic activity may uncover biological pathways underlying this important shared clinical feature.Methods We charted global genetic overlap of the three SMDs, type 2 diabetes (T2D), coronary artery disease (CAD), and body mass index (BMI) with 249 circulating metabolic markers through linkage disequilibrium score regression and bivariate Gaussian mixture modeling. We estimated causal relationships, functionally annotated shared genetic variants, and investigated enrichment across diverse brain and body tissues.Results All three SMDs had extensive overlap with the metabolic markers. The pattern of genetic correlations was highly similar between MDD, T2D, CAD, and BMI (Spearman’s correlation rs>.93), opposite in direction to the pattern found for SCZ and BIP (MDD-BIP rs=-.74; MDD-SCZ rs=-.83). The metabolic markers had widespread, robust causal effects on the SMDs and cardiometabolic traits. We mapped 1056 genes shared between the individual SMDs and the metabolic markers to disorder-specific processes related to metabolic activity, mitochondrial function, and synaptic processes. These genes were most prominently expressed throughout the brain, heart and liver.Discussion SMDs have strong associations with metabolic markers, whereby MDD has a distinctly different genetic relationship than BIP and SCZ. Our findings suggest that metabolic pathways are involved in the development of SMDs and can play a central role in disentangling disorder-specific etiologies. Our “metabolic psychiatry” approach has high potential to guide the development of targeted interventions.Competing Interest StatementOAA has received speakers honorarium from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. AMD was a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and the Mohn Medical Imaging and Visualization Centre in Bergen, Norway. He receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. All other authors report no potential conflicts of interest.Funding StatementThe authors were funded by the Research Council of Norway (296030, 324252, 324499, 326813, 334920, 351751); the South-Eastern Norway Regional Health Authority (2020060); European Union Horizon 2020 Research and Innovation Programme (Grant No. 847776; CoMorMent and Grant No. 964874; RealMent); EU Horizon Psych-STRATA project (#101057454), the Estonian Research Council (PSG615); The University of Tartu grant (PLTGI24925); National Institutes of Health (NIH; U24DA041123; R01AG076838; U24DA055330; and OT2HL161847).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the UKB, we obtained data under accession number 27412. It has received ethics approval from the National Health Service National Research Ethics Service (ref 11/NW/0382), and obtained informed consent from its participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data incorporated in this work were gathered from public resources. The code is available via https://github.com/precimed (GPLv3 license). Correspondence and requests for materials should be addressed to d.v.d.meer[at]medisin.uio.no